Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Growth hormone in children and adolescents with a Prader-Willi-like phenotype
NL-OMON48505Phase 3Terminated
- Sponsor
- Dutch Growth Research Foundation
- Start
- Sep 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of somatropin in Prader-Willi-like syndrome (PWLS) (2 arms), sponsored by Dutch Growth Research Foundation. Primary endpoint: Change in body fat percentage at 6 months. Started Sep 2019; status: terminated.
02
Drugs
somatropin
03
Conditions
Prader-Willi-like syndrome (PWLS)
Beyond the preview
Go deeper on NL-OMON48505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48505.